» Articles » PMID: 34351003

Patient Characteristics and Acute Cardiovascular Event Rates Among Patients with Very High-risk and Non-very High-risk Atherosclerotic Cardiovascular Disease

Overview
Journal Clin Cardiol
Date 2021 Aug 5
PMID 34351003
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The risk for subsequent major cardiovascular (CV) events among patients with very high-risk (VHR) atherosclerotic CV disease (ASCVD) remains to be fully elucidated.

Hypothesis: We assessed the characteristics and major CV event rates of patients with VHR versus non-VHR ASCVD in a real-world setting in the United States (US), hypothesizing that patients with VHR ASCVD would have higher CV event rates.

Methods: This was a retrospective cohort study conducted from January 01, 2011, to June 30, 2018, in the US using the Prognos LDL-C database linked to the IQVIA PharMetrics Plus® database supplemented with the IQVIA prescription claims (Dx/LRx) databases. Patients were ≥18 years old and had  ≥2 non-ancillary medical claims in the linked databases at least 30 days apart. The study was conducted in 2 stages: (1) identification of patients with ASCVD who met the definition of VHR ASCVD and a matched cohort of non-VHR ASCVD patients using the incidence density sampling (IDS) approach; (2) estimation of the occurrence of major CV events.

Results: Among patients with ≥1 major ASCVD event (N=147,679), most qualified as VHR ASCVD (79.5%). There were 115,460 patients each in IDS-matched VHR and non-VHR ASCVD cohorts. The composite myocardial infarction/ischemic stroke event rates in the VHR and non-VHR ASCVD cohorts were 8.04 (95% confidence interval [95% CI]: 7.87-8.22) and 0.82 (95% CI: 0.77-0.88) events per 100 patient-years, respectively, during the 1-year post-index period.

Conclusions: Most patients with ≥1 previous major ASCVD event treated in real-world US clinical practice qualified as VHR ASCVD. Patients with VHR ASCVD had much higher rates of major CV events versus non-VHR ASCVD patients.

Citing Articles

IL-6 and Cardiovascular Risk: A Narrative Review.

Mehta N, deGoma E, Shapiro M Curr Atheroscler Rep. 2024; 27(1):12.

PMID: 39589436 PMC: 11599326. DOI: 10.1007/s11883-024-01259-7.


Prevalence of Tendon Rupture and Tendinopathies Among Patients with Atherosclerotic Cardiovascular Disease Derived From United States Administrative Claims Data.

Gillard K, Bloedon L, Grady-Benson J, Edwards A, Fahy S, Sasiela W Cardiol Ther. 2024; 13(3):575-591.

PMID: 39003659 PMC: 11333683. DOI: 10.1007/s40119-024-00374-5.


The Role of Endothelial Progenitor Cells in Atherosclerosis and Impact of Anti-Lipemic Treatments on Endothelial Repair.

Altabas V, Kirigin Bilos L Int J Mol Sci. 2022; 23(5).

PMID: 35269807 PMC: 8910333. DOI: 10.3390/ijms23052663.


Patient characteristics and acute cardiovascular event rates among patients with very high-risk and non-very high-risk atherosclerotic cardiovascular disease.

Fonarow G, Kosiborod M, Rane P, Nunna S, Villa G, Habib M Clin Cardiol. 2021; 44(10):1457-1466.

PMID: 34351003 PMC: 8495090. DOI: 10.1002/clc.23706.

References
1.
Fonarow G, van Hout B, Villa G, Arellano J, Lindgren P . Updated Cost-effectiveness Analysis of Evolocumab in Patients With Very High-risk Atherosclerotic Cardiovascular Disease. JAMA Cardiol. 2019; 4(7):691-695. PMC: 6551584. DOI: 10.1001/jamacardio.2019.1647. View

2.
Gencer B, Mach F, Murphy S, De Ferrari G, Huber K, Lewis B . Efficacy of Evolocumab on Cardiovascular Outcomes in Patients With Recent Myocardial Infarction: A Prespecified Secondary Analysis From the FOURIER Trial. JAMA Cardiol. 2020; 5(8):952-957. PMC: 7240652. DOI: 10.1001/jamacardio.2020.0882. View

3.
Richardson D . An incidence density sampling program for nested case-control analyses. Occup Environ Med. 2004; 61(12):e59. PMC: 1740694. DOI: 10.1136/oem.2004.014472. View

4.
Superko H, Williams P, Dansinger M, Schaefer E . Trends in low-density lipoprotein-cholesterol blood values between 2012 and 2017 suggest sluggish adoption of the recent 2013 treatment guidelines. Clin Cardiol. 2018; 42(1):101-110. PMC: 6436509. DOI: 10.1002/clc.23115. View

5.
Lentine K, Schnitzler M, Abbott K, Bramesfeld K, Buchanan P, Brennan D . Sensitivity of billing claims for cardiovascular disease events among kidney transplant recipients. Clin J Am Soc Nephrol. 2009; 4(7):1213-21. PMC: 2709516. DOI: 10.2215/CJN.00670109. View